IND Firms Contend Lax NDI Notification Enforcement Threatens Their Chances
Executive Summary
Three pharma submit similar complaints to FDA's NAC docket stating the FDA isn’t sufficiently protecting their interests by allowing use of dietary ingredients similar to the drugs they’re developing.
You may also be interested in...
In NAC Docket, NAD+ Drug Firm Suggests US FDA Get Serious About Dietary Ingredient Regulations
MetroBiotech argues it and other drug developers and manufacturers are harmed as FDA allows NAD+ use in dietary supplements without requiring new dietary ingredient notifications and despite DSHEA’s preclusion clause.
Drug Innovation Needs Exclusivity For Some Natural Substances, PhRMA Recommends
In comments on VMS industry oversight, PhRMA recommends FDA adhere to clear regulations that determine whether substances are eligible for use as dietary ingredients. DSHEA makes clear that some dietary ingredients are not eligible for use VMS products.
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.